Your browser does not support iframes.
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
ALKERMES
(NQ:
ALKS
)
29.45
USD
-0.46 (-1.54%)
Streaming Delayed Price
/ Updated:
1:37 PM EDT, Jun 19, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
457,615
Open
29.82
Bid (Size)
29.44 (100)
Ask (Size)
29.45 (300)
Prev. Close
29.91
Today's Range
29.10 - 30.04
52wk Range
15.69 - 34.30
Shares Outstanding
131,930,050
Dividend Yield
N/A
Top News
More News
UPDATE: Bank of America Lowers PO on Alkermes on Reduced Bydureon Forecast
Today 11:10 EDT
In a report published on Wednesday, Bank of America analyst Steve Byrne lowered the price objective on Alkermes (NASDAQ: ALKS ) from $29 to $27 and maintained an Underperform rating on the company. In...
Read More
category
Benzinga
,
Bank of America
,
ALKS
, and 4 more.
from
Latest Articles from Benzinga.com
Alkermes Up 33.0% Since SmarTrend Uptrend Call (ALKS)
June 12, 2013
from
Comtex SmarTrend® News Briefs
More News
Read More
Alkermes Shares Up 33.9% Since SmarTrend's Buy Recommendation (ALKS)
June 05, 2013
from
Comtex SmarTrend® News Briefs
Bio-Wire Equity Surveillance – Closing Bell 5/31/2013
May 31, 2013
category
Bio/Wire
from
Bio-Wire.Com
Alkermes Issues Positive Results from Phase 2 Study of ALKS 5461
May 31, 2013
category
Benzinga
,
ALKS
,
News
, and 1 more.
from
Latest Articles from Benzinga.com
Alkermes (ALKS) Issues Positive Update for ALKS 5461 Phase 2
May 31, 2013
from
StreetInsider.com News Articles
Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting
May 31, 2013
from
Business Wire News Releases
Free Research Reports on ALKS, DSW, JPM and SONS Issued by the Paragon Report
May 30, 2013
from
Marketwired News Releases
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences
May 29, 2013
from
Business Wire News Releases
Notable Analyst Rating Changes 05/29: (ADI) (ENOC) (SONS) Upgraded; (MXIM) (CMA) (BRCD) Downgraded
May 29, 2013
from
StreetInsider.com News Articles
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.